0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MetaStat
Its shares trade under the ticker MTST. It has been listed since 13 February 2008. In the fiscal year to 28 February 2018, it reported revenue of $23,300 and a net loss of $3.2m. At that date it held total assets of $729,634 and shareholders' equity of −$1.5m.
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. The company is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 13 Feb 2008
- Employees
- 6
Leadership
Pay as last reported
- Dr. Jerome ZeldisChairman of the Board, since 2016$70,500
- Mr. Douglas HamiltonPresident, Chief Executive Officer, Director, since 2015$624,194
- Mr. Daniel SchneidermanVice President - Finance$287,019
- Dr. Paul BillingsDirector$44,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MetaStat Inc possesses several key strengths that contribute to its success in the market. Firstly, the company has proprietary technology and expertise in the field of metastasis detection and analysis, giving it a competitive advantage over rivals. This allows MetaStat to develop innovative diagnostic tools and solutions that address critical unmet needs in cancer management.
- Secondly, MetaStat has established a strong network of strategic partnerships and collaborations with leading research institutions, medical centers, and industry players. This not only enhances its research capabilities but also provides opportunities for product development and commercialization.
- Lastly, MetaStat Inc benefits from a highly skilled and experienced management team. Their leadership and industry knowledge enable the company to make informed decisions, navigate challenges, and drive growth effectively.
Weaknesses
- Despite its strengths, MetaStat Inc faces certain weaknesses that need to be addressed. One such weakness is its relatively small market presence compared to larger competitors. This limits the company's overall brand visibility and market reach, potentially hindering its growth potential in the industry.
- Additionally, MetaStat Inc relies heavily on research and development activities, which can be costly and time-consuming. This poses a financial risk if the company's investments in R&D do not yield desired outcomes or if there are delays in product commercialization.
- Furthermore, MetaStat Inc may face challenges related to regulatory approvals and compliance requirements for its diagnostic products. Stringent regulations governing the healthcare industry can create obstacles and slow down the path to commercialization.
Opportunities
- MetaStat Inc can capitalize on several opportunities in the market to drive growth and expand its market share. One key opportunity lies in the increasing global prevalence of cancer, specifically metastatic cancer. This growing patient population presents a significant market for MetaStat's metastasis detection and management solutions.
- Another opportunity for MetaStat is the rising demand for personalized and targeted therapies. By leveraging its expertise in metastasis detection, the company can develop companion diagnostics that help identify patients who will benefit most from specific treatments, leading to improved patient outcomes.
- Additionally, MetaStat Inc can explore international expansion, entering new geographical markets where there is a need for advanced metastasis detection technologies. This can fuel revenue growth and diversify the company's customer base.
Threats
- MetaStat Inc must also be aware of the potential threats it faces in the market. The competitive landscape is a significant threat, with large and established players already offering diagnostic solutions for cancer management. MetaStat needs to continually innovate and differentiate itself to maintain a competitive edge.
- Furthermore, changes in healthcare policies and reimbursement models can pose a threat to MetaStat's business. Alterations in regulations and reimbursement rates can impact the adoption and usage of its diagnostic products, affecting overall revenue and profitability.
- Lastly, technological advancements and the emergence of new diagnostic techniques could render MetaStat's current offerings obsolete or less relevant. It is crucial for the company to stay abreast of technological developments and continuously invest in research to stay ahead of the curve.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.